CA2099970C - Composition for curing sjoegren syndrome disease - Google Patents

Composition for curing sjoegren syndrome disease Download PDF

Info

Publication number
CA2099970C
CA2099970C CA002099970A CA2099970A CA2099970C CA 2099970 C CA2099970 C CA 2099970C CA 002099970 A CA002099970 A CA 002099970A CA 2099970 A CA2099970 A CA 2099970A CA 2099970 C CA2099970 C CA 2099970C
Authority
CA
Canada
Prior art keywords
quinuclidine
composition
disease
oxathiolane
addition salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002099970A
Other languages
English (en)
French (fr)
Other versions
CA2099970A1 (en
Inventor
Nobuaki Abe
Yasuyoshi Takeshita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16540522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2099970(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Publication of CA2099970A1 publication Critical patent/CA2099970A1/en
Application granted granted Critical
Publication of CA2099970C publication Critical patent/CA2099970C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002099970A 1992-07-10 1993-07-06 Composition for curing sjoegren syndrome disease Expired - Lifetime CA2099970C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP207485/1992 1992-07-10
JP4207485A JP2683783B2 (ja) 1992-07-10 1992-07-10 シェーグレン症候群治療剤

Publications (2)

Publication Number Publication Date
CA2099970A1 CA2099970A1 (en) 1994-01-11
CA2099970C true CA2099970C (en) 2003-12-30

Family

ID=16540522

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002099970A Expired - Lifetime CA2099970C (en) 1992-07-10 1993-07-06 Composition for curing sjoegren syndrome disease

Country Status (15)

Country Link
US (1) US5340821A (enExample)
EP (1) EP0578511B1 (enExample)
JP (1) JP2683783B2 (enExample)
KR (1) KR100331046B1 (enExample)
AT (1) ATE184483T1 (enExample)
AU (1) AU666734B2 (enExample)
CA (1) CA2099970C (enExample)
DE (1) DE69326395T2 (enExample)
DK (1) DK0578511T3 (enExample)
ES (1) ES2138613T3 (enExample)
IL (1) IL106218A (enExample)
NO (1) NO303765B1 (enExample)
NZ (1) NZ248099A (enExample)
TW (1) TW230750B (enExample)
ZA (1) ZA934883B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2852608B2 (ja) * 1994-06-27 1999-02-03 雪印乳業株式会社 口腔乾燥症治療剤
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
JP4447685B2 (ja) * 1999-01-14 2010-04-07 第一三共株式会社 皮膚乾燥症治療剤
JP2006070027A (ja) * 2004-08-06 2006-03-16 Dai Ichi Seiyaku Co Ltd 口腔粘膜投与剤
WO2006013914A1 (ja) * 2004-08-06 2006-02-09 Daiichi Pharmaceutical Co., Ltd. 口腔粘膜投与剤
BRPI0516468A (pt) * 2004-10-05 2008-09-09 Astellas Pharma Inc composição farmacêutica para o tratamento de xeroftalmia e xerostomia
AU2006282896A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8143400B2 (en) * 2008-01-10 2012-03-27 Apotex Pharmachem Inc. Process for the preparation and purification of cis-2-methylspiro(1,3-oxathiolane-5,3′)quiniclidine hydrochloride
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
SI2498771T1 (sl) 2009-11-12 2014-04-30 Acacia Pharma Limited Uporaba betanekola za zdravljenje kserostomije
GB201107533D0 (en) 2011-05-06 2011-06-22 Acacia Pharma Ltd Formulaiton
CN102846607A (zh) * 2012-04-09 2013-01-02 珠海亿邦制药股份有限公司 一种以盐酸西维美林为活性成分的固体制剂及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001396A (en) * 1971-08-04 1977-01-04 Chinoin Pharmaceutical And Chemical Works Ltd. Hormonal product extracted from parathyroid gland and process for the preparation thereof
US4110441A (en) * 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4701450A (en) * 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
US4684727A (en) * 1985-07-29 1987-08-04 Schering Corporation Zwitterionic 1,8-naphthyridine and pyrazino[2,3-b]pyridine containing compounds useful as anti-allergic, anti-inflammatory and cycloprotective agents
ZA868369B (en) * 1986-01-10 1987-11-25 Israel State Derivatives of quinuclidine
GB8717446D0 (en) * 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US4876260A (en) * 1987-10-28 1989-10-24 State Of Israel, Israel Institute Of Biological Research Oxathiolanes
CA1303503C (en) * 1987-11-10 1992-06-16 Marc Plamondon Ophthalmic solution comprising iodine-polyvinylpyrrolidone complex
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US4997654A (en) * 1989-08-14 1991-03-05 Warner-Lambert Company Method for increasing salivation for xerostomia patients
DE69220258T2 (de) * 1991-02-11 1997-12-18 Merck Sharp & Dohme Azabicyclische Verbindungen, diese enthaltende pharmazeutische Zubereitungen und ihre therapeutische Verwendung

Also Published As

Publication number Publication date
US5340821A (en) 1994-08-23
DE69326395T2 (de) 2000-04-20
NO932520L (no) 1994-01-11
TW230750B (enExample) 1994-09-21
NO303765B1 (no) 1998-08-31
IL106218A0 (en) 1993-11-15
DK0578511T3 (da) 2000-04-03
AU4181993A (en) 1994-01-13
DE69326395D1 (de) 1999-10-21
AU666734B2 (en) 1996-02-22
JPH0624981A (ja) 1994-02-01
NO932520D0 (no) 1993-07-09
KR100331046B1 (ko) 2002-08-19
EP0578511A1 (en) 1994-01-12
CA2099970A1 (en) 1994-01-11
KR940005274A (ko) 1994-03-21
IL106218A (en) 1997-02-18
ES2138613T3 (es) 2000-01-16
ZA934883B (en) 1994-02-03
NZ248099A (en) 1999-07-29
EP0578511B1 (en) 1999-09-15
ATE184483T1 (de) 1999-10-15
JP2683783B2 (ja) 1997-12-03

Similar Documents

Publication Publication Date Title
CA2099970C (en) Composition for curing sjoegren syndrome disease
US5580880A (en) Method for the treatment of xerostomia
CA2231764A1 (en) Tumor necrosis factor alpha (tnf-.alpha.) inhibiting pharmaceuticals
JP2002527474A (ja) 躁病および双極性障害の治療法
US20230129151A1 (en) Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
CZ355897A3 (cs) Způsob léčení mánie a bipolárních poruch
IE58734B1 (en) Use of propiophenone compounds
KR0133555B1 (ko) 5-플루오로우라실계 화합물에 기인한 염증의 발생을 억제할 수 있는 비-주사제 형태의 항암조성물
JP2872695B2 (ja) 腎炎の治療剤
JPH10298077A (ja) 心筋症の治療、予防剤
JPH0723387B2 (ja) ピペラジンカルボン酸、その製造方法およびそれを含有する医薬組成物
KR20210047887A (ko) 중첩발작의 예방, 경감 또는 치료에 대한 카바메이트 화합물의 용도
RU2700595C1 (ru) Производное 3,6,9-триазатрициклотетрадекана и его применение для лечения депрессии
AU760180B2 (en) Dry skin remedies
KR20230015433A (ko) 운동실조를 치료하기 위한 아세틸 류신과 4-아미노피리딘 또는 아세타졸아미드의 조합물
KR920003580B1 (ko) 동맥경화증 예방 및 치료제
JP2636265B2 (ja) 脳循環改善剤
US20100069312A1 (en) Aminoalkyl glucosamine phosphate compounds for treating autoimmune diseases
JPH0236190A (ja) アミノ安息香酸誘導体よりなる抗脳疾患剤
JPH0892089A (ja) ドライバジャイナ治療剤
JPH05194463A (ja) フラノン誘導体を含有する医薬組成物
JP2002114681A (ja) 勃起不全治療剤
PT1827461E (pt) Regime posológico de cladribina para o tratamento de esclerose múltipla

Legal Events

Date Code Title Description
EEER Examination request